Bank of America
IBRX icon

Bank of America’s ImmunityBio IBRX Stock Holding History

Bank of America’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,000
Closed -$10.7K – 8312
2024
Q1 		$10.7K Buy
+2,000
New +$9.06K ﹤0.01% 6875

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bank of America's IBRX Position: Q1 2026 in Review

Bank of America increased its ImmunityBio (IBRX) stake by 2.7% in Q1 2026, buying an estimated $447K and bringing the position to 2,447,843 shares worth $18.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

Bank of America first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. The position peaked at $23.1M in Q2 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Bank of America held 2,447,843 shares of ImmunityBio worth $18.8M as of Q1 2026.
  • Bank of America bought 65,340 ImmunityBio shares in Q1 2026, an estimated $447K.
  • ImmunityBio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2444 holding.
  • Bank of America first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
  • Bank of America's ImmunityBio position peaked at $23.1M in Q2 2025.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.